IL152545A0 - Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect - Google Patents

Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Info

Publication number
IL152545A0
IL152545A0 IL15254501A IL15254501A IL152545A0 IL 152545 A0 IL152545 A0 IL 152545A0 IL 15254501 A IL15254501 A IL 15254501A IL 15254501 A IL15254501 A IL 15254501A IL 152545 A0 IL152545 A0 IL 152545A0
Authority
IL
Israel
Prior art keywords
effect
bicalutamide
tamoxifen
providing
pharmaceutical combination
Prior art date
Application number
IL15254501A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL152545A0 publication Critical patent/IL152545A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15254501A 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect IL152545A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0012291.1A GB0012291D0 (en) 2000-05-23 2000-05-23 Pharmaceutical combination
PCT/SE2001/001162 WO2001089515A1 (en) 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Publications (1)

Publication Number Publication Date
IL152545A0 true IL152545A0 (en) 2003-05-29

Family

ID=9892038

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15254501A IL152545A0 (en) 2000-05-23 2001-05-22 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect

Country Status (23)

Country Link
US (1) US20030134899A1 (xx)
EP (1) EP1292296A1 (xx)
JP (1) JP2003534278A (xx)
KR (1) KR20030001535A (xx)
CN (1) CN1431899A (xx)
AU (1) AU2001262833A1 (xx)
BR (1) BR0111051A (xx)
CA (1) CA2407028A1 (xx)
CZ (1) CZ20023785A3 (xx)
EE (1) EE200200654A (xx)
GB (1) GB0012291D0 (xx)
HK (1) HK1053061A1 (xx)
HU (1) HUP0302276A3 (xx)
IL (1) IL152545A0 (xx)
IS (1) IS6589A (xx)
MX (1) MXPA02011472A (xx)
NO (1) NO20025638L (xx)
NZ (1) NZ521979A (xx)
PL (1) PL363504A1 (xx)
RU (1) RU2002134483A (xx)
SK (1) SK16562002A3 (xx)
WO (1) WO2001089515A1 (xx)
ZA (1) ZA200208845B (xx)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
DK1460969T3 (da) * 2001-11-29 2008-09-01 Gtx Inc Forebyggelse og behandling af ved androgen-berövelse fremkaldt osteoporose
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
JP2008534575A (ja) * 2005-03-29 2008-08-28 ユーエスヴィー リミテッド ビカルタミドの調製のための新規プロセス
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (xx) * 1962-09-13
EP0100172B1 (en) * 1982-07-23 1987-08-12 Imperial Chemical Industries Plc Amide derivatives
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
CA2181358A1 (en) * 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex

Also Published As

Publication number Publication date
NZ521979A (en) 2004-06-25
GB0012291D0 (en) 2000-07-12
CA2407028A1 (en) 2001-11-29
EE200200654A (et) 2004-06-15
WO2001089515A1 (en) 2001-11-29
SK16562002A3 (sk) 2003-05-02
PL363504A1 (en) 2004-11-29
HUP0302276A2 (hu) 2003-11-28
AU2001262833A1 (en) 2001-12-03
RU2002134483A (ru) 2004-06-27
ZA200208845B (en) 2004-02-27
EP1292296A1 (en) 2003-03-19
MXPA02011472A (es) 2004-09-06
HK1053061A1 (zh) 2003-10-10
KR20030001535A (ko) 2003-01-06
CN1431899A (zh) 2003-07-23
HUP0302276A3 (en) 2005-06-28
NO20025638D0 (no) 2002-11-22
JP2003534278A (ja) 2003-11-18
US20030134899A1 (en) 2003-07-17
CZ20023785A3 (cs) 2003-03-12
IS6589A (is) 2002-10-25
BR0111051A (pt) 2003-04-15
NO20025638L (no) 2002-11-22

Similar Documents

Publication Publication Date Title
AU7174101A (en) Pharmaceutical compositions of estrogenic agents
AU4541701A (en) Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB2385524B (en) Compositions and methods of use for extracts of magnoliaceae
ATE260093T1 (de) Aerosoldruckdosiergeräte und aerosolarzneizusammensetzungen
DE60140462D1 (de) Darreichungsform zur hormonalen kontrazeption
HUP0302276A3 (en) Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
PL373494A1 (en) Estrogen/gestagen combination preparation and application thereof
HK1052877A1 (zh) Ssri與雌激素劑之組合
HUP0302478A3 (en) Pharmaceutical solutions of modafinil compounds
AU2001271163A1 (en) Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
PL365582A1 (en) Use of salmeterol and fluticasone propionate combination
GB0213299D0 (en) Construction of dies
PL357020A1 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
GB2367489B (en) Use of antioxidants
IL161608A0 (en) Synthesis of 2-aralkoxyadenosines and 2-alkoxyadenosines
HU0005013D0 (en) Use of polidocanol for the treatment of the uterus and ovary of mammals
AU2001262834A1 (en) Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
GB0021927D0 (en) Use of pharmaceutical combination
TW459541U (en) Structure of permeation-type perfume releasing
TW501484U (en) Structure of perfume device
TW422090U (en) Improved structure of mask
TW510228U (en) Improved structure of mask
TW494759U (en) Improved structure of mask
GB0000068D0 (en) Preparation for treatment of irritant skin conditions
TW445856U (en) Structure of perfume device